FGF2 and neoplasm: With AZ10167514 administration, for both tumour‐bearing and non‐tumour‐bearing animals, there were further increases in the serum concentrations of mouse‐specific basic fibroblast growth factor (bFGF), showing a greater elevation in tumour‐bearing animals, notably at the low dose.